# EDGAR Filing Document

**Accession Number:** 0001267602
**File Stem:** 0001267602-23-000008
**Filing Date:** 2023-3
**Character Count:** 4995
**Document Hash:** 36cfce264098c55f9e8067f94aea94c5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001267602-23-000008.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001267602-23-000008

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230313

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALIMERA SCIENCES INC
- **CENTRAL INDEX KEY:** 0001267602
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 200028718
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34703
- **FILM NUMBER:** 23727908

**BUSINESS ADDRESS:**
- **STREET 1:** 6310 TOWN SQUARE
- **STREET 2:** SUITE 400
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30005
- **BUSINESS PHONE:** 678-990-5740

**MAIL ADDRESS:**
- **STREET 1:** 6310 TOWN SQUARE
- **STREET 2:** SUITE 400
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30005

?xml version="1.0" encoding="utf-8"? alim-20230313x8k

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT** 

**PURSUANT TO SECTION 13 OR 15(D) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): March 13, 2023

## ALIMERA SCIENCES, INC.
(Exact name of registrant as specified in its charter)

---

| | | | |
|:---|:---|:---|:---|
| **Delaware** | **001-34703** | **001-34703** | **20-0028718** |
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (Commission File Number) | (IRS Employer Identification No.) |
| **6310 Town Square, Suite 400**<br>**Alpharetta, Georgia** | **6310 Town Square, Suite 400**<br>**Alpharetta, Georgia** | **30005**  | **30005**  |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) | (Zip Code) |

---

Registrant's telephone number, including area code: **(678) 990-5740**

---

| |
|:---|
| **Not Applicable** |
| (Former name or former address if changed since last report.) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| &nbsp;&nbsp;Title of each class | &nbsp;&nbsp;Name of each exchange on which registered |
| &nbsp;&nbsp;Common Stock, $0.01 par value per share<br> &nbsp;&nbsp;ALIM | &nbsp;&nbsp;The Nasdaq Stock Market LLC<br>(Nasdaq Global Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 7.01. Regulation FD Disclosure**

Alimera Sciences, Inc. (the "Company") is aware of the closures of Silicon Valley Bank ("SVB") and Signature Bank ("Signature") and appointment of the Federal Deposit Insurance Corporation as receiver of each of those entities. The Company does not hold cash deposits or securities with SVB or Signature and does not otherwise have a business relationship with either SVB or Signature.

The information in this Current Report on Form 8-K under Item 7.01 is being "furnished" and not "filed" with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities under such section. Furthermore, such information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless specifically identified as being incorporated therein by reference.

 **‎** 

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | ALIMERA SCIENCES, INC. | ALIMERA SCIENCES, INC. |
| Dated: March 13, 2023 | By: | /s/ Russell L. Skibsted |
|  | Name: | Russell L. Skibsted |
|  | Title: | Chief Financial Officer and Senior Vice President |

---